Literature DB >> 22012231

The presence of Helicobacter pylori in the liver depends on the Th1, Th17 and Treg cytokine profile of the patient.

Luciana Diniz Silva1, Andreia Maria Camargos Rocha, Gifone Aguiar Rocha, Sílvia Beleza de Moura, Márcia Maria Negreiros Pinto Rocha, Renato Dani, Fabrício Freire de Melo, Juliana Becattini Guerra, Lúcia Porto Fonseca de Castro, Guilherme Santiago Mendes, Teresa Cristina de Abreu Ferrari, Agnaldo Soares Lima, Dulciene Maria Magalhães Queiroz.   

Abstract

The hypothesis that Helicobactermight be a risk factor for human liver diseases has arisen after the detection of Helicobacter DNA in hepatic tissue of patients with hepatobiliary diseases. Nevertheless, no explanation that justifies the presence of the bacterium in the human liver has been proposed. We evaluated the presence of Helicobacterin the liver of patients with hepatic diseases of different aetiologies. We prospectively evaluated 147 patients (106 with primary hepatic diseases and 41 with hepatic metastatic tumours) and 20 liver donors as controls. Helicobacter species were investigated in the liver by culture and specific 16S rDNA nested-polymerase chain reaction followed by sequencing. Serum and hepatic levels of representative cytokines of T regulatory cell, T helper (Th)1 and Th17 cell lineages were determined using enzyme linked immunosorbent assay. The data were evaluated using logistic models. Detection of Helicobacter pylori DNA in the liver was independently associated with hepatitis B virus/hepatitis C virus, pancreatic carcinoma and a cytokine pattern characterised by high interleukin (IL)-10, low/absent interferon-γ and decreased IL-17A concentrations (p < 10(-3)). The bacterial DNA was never detected in the liver of patients with alcoholic cirrhosis and autoimmune hepatitis that are associated with Th1/Th17 polarisation. H. pylori may be observed in the liver of patients with certain hepatic and pancreatic diseases, but this might depend on the patient cytokine profile.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012231     DOI: 10.1590/s0074-02762011000600016

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  6 in total

1.  Helicobacter pylori Infection Status Correlates with Serum Parameter Levels Responding to Multi-organ Functions.

Authors:  Yuehua Gong; Wang Wei; Liu Jingwei; Dong Nannan; Yuan Yuan
Journal:  Dig Dis Sci       Date:  2015-01-20       Impact factor: 3.199

2.  Helicobacter pylori infection does not promote hepatocellular cancer in a transgenic mouse model of hepatitis C virus pathogenesis.

Authors:  Alexis García; Yan Feng; Nicola M A Parry; Amanda McCabe; Melissa W Mobley; Kvin Lertpiriyapong; Mark T Whary; James G Fox
Journal:  Gut Microbes       Date:  2013-08-07

3.  Serum Interleukin (IL)-9 and IL-10, but not T-Helper 9 (Th9) Cells, are Associated With Survival of Patients With Acute-on-Chronic Hepatitis B Liver Failure.

Authors:  Xueping Yu; Yijuan Zheng; Yong Deng; Julan Li; Ruyi Guo; Milong Su; Desong Ming; Zhenzhong Lin; Jiming Zhang; Zhijun Su
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  Helicobacter pylori infection among patients with liver cirrhosis.

Authors:  Joanna Pogorzelska; Magda Łapińska; Alicja Kalinowska; Tadeusz W Łapiński; Robert Flisiak
Journal:  Eur J Gastroenterol Hepatol       Date:  2017-10       Impact factor: 2.566

5.  Evolution of correlation between Helicobacter pylori infection and autoimmune liver disease.

Authors:  Xin-Guo Peng; Yu-Yuan Li; Hui-Ting Chen; Yan Zhou; Jian-Guo Ma; Hong-Min Yin
Journal:  Exp Ther Med       Date:  2017-06-27       Impact factor: 2.447

6.  Both diet and Helicobacter pylori infection contribute to atherosclerosis in pre- and postmenopausal cynomolgus monkeys.

Authors:  Traci L Testerman; Cristina Semino-Mora; Jennifer A Cann; Beidi Qiang; Edsel A Peña; Hui Liu; Cara H Olsen; Haiying Chen; Susan E Appt; Jay R Kaplan; Thomas C Register; D Scott Merrell; Andre Dubois
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.